For those of you who don’t follow us on social media (you’re missing out! Now's your chance!)

Last week was a big week for us—we launched AdverseEvents Explorer at the Academy of Managed Care Pharmacists (AMCP) conference down in Tampa, FL. It was a fantastic conference and it was extremely reassuring to talk directly to our target market and receive almost a unanimously positive response.

Aside from fulfilling my need for constant validation, the conference was a great teaching venue for me. While our Business Development Managers were hard at work relaying our value proposition at the booth, I got a chance to sit in on some of the sessions designed for managed care pharmacists, as well as talk with the thought leaders that were doing the teaching.

Comparable Effectiveness Research (CER) was a major theme. AMCP in partnership with Dymaxium has recently rolled out their eDossiers software that allow healthcare decision makers (HCDMs) to easily get to the information needed to perform evaluations and come to hard and fast, evidence based conclusions on the comparable efficacy of the products within a class of drugs. Two of the sessions that I attended on the topic included executives from OmedaRx as a presenter. The work that they are doing with their clients is fantastic-- data driven techniques that allow for efficient and consistent decision making.

There was however, what I felt to be (and what others thought as well based on questions that I heard being asked), a large gap in these frameworks. While dealing with the comparable effectiveness of medications was exhaustive and hit on almost every imaginable measure, the drug safety components of these frameworks were, for lack of a better word, weak. Adverse drug events were dealt with in broad strokes and in many circumstances applied based on what has been seen on a class wide basis.

This is not overly surprising. While mitigating drug side effects is front of mind for HCDMs, they do not have an easy way to compare the safety profiles of drugs. There has not been a framework developed, or the data, or software available to effectively make risk comparisons that stack up to what is being done with CER. Furthermore, true drug safety profiles are not known until a drug comes to market. HCDMs do not have any way to currently take that information into account, as Industry is not disclosing ADEs that are not on label.

Until now. If you haven’t seen it, take a look at our press release announcing the launch of AdverseEvents Explorer.

There are methodologies that can be used to create a proper framework for Comparable Safety Research (CSR) that not only use what was seen in trials, but also what is being reported post-marketing. The technology, the data, and the analytics exist to be able to compliment the benefit shown via CER with the risk shown through CSR.

The best part is, that it doesn’t require extensive additional work or pharmacist hours or large consulting fees (unless you want to!). See for yourself. Start a 7-day trial of AdverseEvents Explorer and talk with one of our CSR experts.

 


Post FDA approval drug safety whitepaper - Download Now

Jim Davis

Jim Davis

Executive Vice President

Jim Davis LinkedinJim Davis Twitter

 

Topics: Drug Safety, Evidex

Jim Davis

Written by Jim Davis

As Executive Vice President, Jim is responsible for the commercialization strategy for Advera Health Analytics.